MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021
December 01 2021 - 10:05AM
Business Wire
MyMD to highlight its development pipeline for
two novel therapeutics: immune regulator MYMD-1 and synthetic
cannabidiol derivative Supera-CBD
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan by delaying aging, today announced that
it will participate in two investor conferences during the month of
December 2021.
Benchmark Company Discovery Conference
Date:
December 2, 2021
Format:
1-on-1 meetings (virtual)
Registration:
Click here
Benzinga Global Small Cap Conference
Dates:
December 8-9, 2021
Format:
Presentation and 1x1 meetings
(virtual)
Presentation time:
Wednesday, December 8 at 4:00 p.m. ET –
Adam Kaplin, M.D., Ph.D., Chief Scientific Officer
Registration:
Click here
Livestream:
Click here
During the conferences, MyMD executives will discuss the
multiple indications being pursued and market opportunities for
novel drug candidates MYMD-1 and Supera-CBD.
About MYMD-1 Originally developed for autoimmune
diseases, MYMD-1’s primary purpose is to slow the aging process,
prevent sarcopenia and frailty, and extend healthy lifespan.
Because it can cross the blood-brain barrier and gain access to the
central nervous system (CNS), MYMD-1 is also positioned to be a
possible treatment for brain-related disorders. Its mechanism of
action and efficacy in diseases including multiple sclerosis (MS)
and thyroiditis have been studied through collaborations with
several academic institutions. MYMD-1 is also showing promise in
pre-clinical studies as a potential treatment for post- COVID-19
complications and as an anti-fibrotic and anti-proliferation
therapeutic.
MYMD-1 has shown effectiveness in pre-clinical studies in
regulating the immune system by performing as a selective inhibitor
of tumor necrosis factor-alpha (TNF-α), a driver of chronic
inflammation. Unlike other therapies, MYMD-1 has been shown in
these pre-clinical studies to selectively block TNF-α when it
becomes overactivated in autoimmune diseases and cytokine storms,
but not block it from doing its normal job of being a first
responder to any routine type of moderate infection. MYMD-1’s ease
of oral dosing is another differentiator compared to currently
available TNF-α blockers, all of which require delivery by
injection or infusion. No approved TNF inhibitor has ever been
dosed orally. In addition, the drug is not immunosuppressive and
has not been shown to cause the serious side effects common with
traditional therapies that treat inflammation.
About Supera-CBD Supera-CBD is MyMD’s pre-clinical
patented synthetic cannabidiol (CBD) derivative that is being
developed as a pharmaceutical drug to address anxiety, pain, and
neurodegeneration. Supera-CBD targets the cannabinoid receptor type
2 (CB2), a protein mainly expressed in the immune system and which
is associated with the therapeutic effects of CBD, including its
anxiolytic, anticonvulsant, antipsychotic, neuroprotective and
anti-inflammatory properties. CB2 receptors do not create an
intoxicating negative psychotropic reaction (e.g. a high). In
contrast, CB1 is usually expressed in the brain and distributed
throughout the central nervous system to deliver an intoxicating
effect. A vast majority of CBD developers are pursuing compounds
targeted to CB2 that have minimal CB1 affinity. MyMD’s Supera-CBD,
with low CB1 affinity and four-fold increased CB2 binding, is 8,000
times more potent a CB2 agonist (activator) than regular CBD. The
Company believes that Supera-CBD is currently on a path toward
human clinical trials as a therapy for epilepsy, followed by
chronic pain.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
rather than only addressing the symptoms. MYMD-1 is a drug platform
based on a clinical stage small molecule that regulates the immune
system to control TNF-α, which drives chronic inflammation, and
other pro-inflammatory cell signaling cytokines. MYMD-1 is being
developed to delay aging, increase longevity, and treat autoimmune
diseases and COVID-19- associated depression. The Company’s second
drug platform, Supera-CBD, is being developed to treat chronic
pain, addiction and epilepsy. Supera-CBD is a novel synthetic
derivative of cannabidiol (CBD) and is being developed to address
and improve upon the rapidly growing CBD market, which includes
both FDA approved drugs and CBD products not currently regulated as
drugs. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 2021, filed by MyMD on
November 12, 2021 (as amended on November 15, 2021).
Forward-looking statements speak only as of the date they are made
and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211201005157/en/
Robert Schatz (646) 421-9523 rschatz@mymd.com www.mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024